Navigation Links
Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/6/2008

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 11:10 a.m. ET. The event will be held at the New York Palace Hotel from November 10-12, 2008.

A live audio webcast of the presentation will be available at: http://www.wsw.com/webcast/rrshq14/oncy or on the company's website at http://www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible following the presentation at http://www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward- looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
2. Progress toward new storage media
3. Edmonton's Technology Community: Using Social Media to Raise Awareness
4. Katrina Proven Certified Organic Toxic Mold Remedy Now Available for Mold Remediation Professionals and Homeowners
5. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
6. Six Sigma and Social Media: Tools for Reducing Costs, Improving Processes
7. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
8. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
9. Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008
10. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
11. U.S. News Media Group Releases 19th Edition of Americas Best Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... Researchers from a new study are stating that if levels of ... cancer treatment, this indicates there is still remaining prostate cancer cells that are more likely ... test has always been an indicator of whether a man’s prostate cancer is growing ...
(Date:1/18/2017)... PA (PRWEB) , ... January 18, 2017 , ... Thirty-six ... in tax credits by the Pennsylvania Department of Community and Economic Development in 2016 ... companies are located in the University City Keystone Innovation Zone and represent the highest ...
(Date:1/18/2017)... 18, 2017 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... company that develops and commercializes proprietary technologies and ... "Company"), today announced that Cameron Prange , ... resigned from its Board of Directors.  Mr. Prange,s ... regulations that have limited both his ability to ...
(Date:1/17/2017)... YORK , Jan. 17, 2017 ... grow at a CAGR of around 7.5% over ... by 2025. Some of the prominent trends that ... growing incidences of diseases & graft transplant surgeries ... on Material the market is categorized into immunomodulatory ...
Breaking Biology Technology:
(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CES® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):